Skip to main content
US EQUITIES PRE-MARKET CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
BL

BLTEStockBelite Bio, Inc

Nasdaq Capital Market · Healthcare · US

$156.23 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment BLTE's does — no target price to set, unlike a price alert.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure2 of 5 timeframes bullish · 69.6% aligned
VWAPPrice below VWAP ($162.96)
VolumeRelative volume 6.1× the 20-day average
Momentum10-day rate of change +1.4%
Market & analysts
Wall Street consensus
BUY
15 analysts
Price target
$233.00
+49.1% · 9 analysts
Institutional own.
24.2%
of shares
Momentum (10d)
+1.4%
rate of change
SMC grade
F · 26
69.6% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
F · 26
SMC grade — 69.6% timeframe alignment
+1.4%
Rate of change (10d)
BUY
Wall Street consensus (15)
$233.00
Price target (+49.1%) · 9 analysts
24.2%
Institutional ownership

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for BLTE — this runs off the critical path so the page paints first. It will appear here on its own.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Tracked investors holding BLTE
InvestorFirmPositionWeightAs of
Lee Ainslie Maverick Capital $104M 0.8% 2026-09-30
Israel Englander Millennium Management $64M 0.0% 2026-09-30
Stanley Druckenmiller Duquesne Family Office $18M 0.4% 2026-09-30
Peter Brown Renaissance Technologies $6M 0.0% 2026-09-30
Steven Cohen Point72 Asset Management $3M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

193.61172.50151.40130.29109.182025-11-192026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
147.73
S2
152.12
S1
154.92
PIVOT
159.31
R1
162.11
R2
166.50
R3
169.30

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
150.57 – 182.75
±9.65% from 166.66, made 2026-09-29 · resolves 2026-10-06
SELL
from 19 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG BUY
3 buy · 4 neutral · 0 sell
Moving averagesSTRONG SELL
2 buy · 0 neutral · 10 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)49.80NEUTRAL
Stochastic %K (14)50.95NEUTRAL
CCI (20)46.13NEUTRAL
Williams %R (14)-49.05NEUTRAL
MACD (12,26,9)1.06BUY
ROC (10)1.44BUY
Momentum (10)2.22BUY
EMA (10)158.14SELL
SMA (10)157.84SELL
EMA (20)156.56SELL
SMA (20)153.93BUY
EMA (30)156.56SELL
SMA (30)153.31BUY
EMA (50)157.36SELL
SMA (50)159.02SELL
EMA (100)157.92SELL
SMA (100)159.35SELL
EMA (200)158.39SELL
SMA (200)159.84SELL

About Belite Bio, Inc

Healthcare · Biotechnology

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

belitebio.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BULLISH 43
⏰ 4H BULLISH 27
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+1.4%
Rate of change (10d)
6.1×
Volume vs its 20-day average
0.56
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

CLUSTER SELL   0 buys · 50 sells

Recent: Lin Yu-Hsin sold 167934 sh @ $180.29 (2026-09-04); Lin Yu-Hsin sold 165347 sh @ $181.24 (2026-09-04); Lin Yu-Hsin sold 161934 sh @ $182.50 (2026-09-04)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.